2024
Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy
Han R, Rao X, Zhou H, Lu L. Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy. International Journal Of Nanomedicine 2024, 19: 4803-4834. PMID: 38828205, PMCID: PMC11144010, DOI: 10.2147/ijn.s461289.Peer-Reviewed Original ResearchConceptsRegulate PD-L1 expressionPD-L1 expressionPD-1/PD-L1Inhibition therapySensitive to immune checkpoint inhibitorsEfficacy of cancer immunotherapyPD-1/PD-L1 inhibitorsImmune checkpoint inhibitorsAnti-cancer immunityEfficacy of monotherapyExploration of combination strategiesModulate immune responsesMRNA vaccine technologyCheckpoint inhibitorsCancer immunotherapyRNA-based therapiesTreatment strategiesImmunomodulatory effectsCancer therapyImmune responseTherapyCancer treatmentVaccine technologyCombination strategiesCancer
2022
Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors
Chen Q, Lu L, Ma W. Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors. Cancers 2022, 14: 5983. PMID: 36497465, PMCID: PMC9739567, DOI: 10.3390/cancers14235983.Peer-Reviewed Original ResearchCAR T-cell therapyT-cell therapyCAR T cellsT cellsSolid tumorsChimeric antigen receptor T-cell therapyAdequate T-cell responsesCytokine release syndromeHalf of patientsT cell responsesTumor antigen targetsRelease syndromeAdoptive immunotherapyClinical efficacyHeterogeneous solid tumorsHematological malignanciesSide effectsTarget antigenAntigen targetsTherapyTumorsCancer treatmentNon-cancer cellsCancer cellsEfficacyBreast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
Yao L, Jia G, Lu L, Ma W. Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies? Current Oncology 2022, 29: 4902-4913. PMID: 35877249, PMCID: PMC9320700, DOI: 10.3390/curroncol29070389.Peer-Reviewed Original ResearchConceptsNeoadjuvant chemotherapyBreast cancer patientsCancer patientsEfficacy of NACHuman leukocyte antigen-DR isotypeInitiation of therapyTumor-infiltrating lymphocytesBenefits of treatmentTumor-associated macrophagesOncotype DXMolecular testingPatientsDecreased levelsCancer cellsChemotherapyTreatmentMammaPrintSurgeryLymphocytesTherapyTumorsMacrophages
2020
Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors
Yao L, Jia G, Lu L, Bao Y, Ma W. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. International Immunopharmacology 2020, 85: 106628. PMID: 32474388, DOI: 10.1016/j.intimp.2020.106628.Peer-Reviewed Original ResearchConceptsImmune-related adverse effectsImmune checkpoint inhibitorsICI therapyCheckpoint inhibitorsCancer patientsPredictive biomarkersTumor respondersAnti-PD-1/PD-L1 immunotherapyCell death protein 1 (PD-1) pathwayT-lymphocyte-associated antigen 4PD-L1 immunotherapyVariety of malignanciesAdvanced human cancersConventional anticancer therapiesDegree of severityProtein 1 pathwayNew potential mechanismAntigen-4Cancer immunotherapyToxicity profileImmunotherapyTherapyPatientsAdverse effectsAnticancer therapy
2019
Exosomal MicroRNAs Associate With Neuropsychological Performance in Individuals With HIV Infection on Antiretroviral Therapy.
OʼMeara T, Kong Y, Chiarella J, Price RW, Chaudhury R, Liu X, Spudich S, Robertson K, Emu B, Lu L. Exosomal MicroRNAs Associate With Neuropsychological Performance in Individuals With HIV Infection on Antiretroviral Therapy. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 82: 514-522. PMID: 31714431, PMCID: PMC6857839, DOI: 10.1097/qai.0000000000002187.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyNeuropsychological performanceAntiretroviral therapyViral suppressionHIV infectionNeurocognitive dysfunctionExo-miRNAsEarly infection groupCentral nervous systemSystemic viral suppressionTyrosine receptor kinaseInfection groupChronic infectionPLWHCross-sectional examinationNervous systemEarly infectionNeuropsychological scoresInfectionConsistent findingNeuropsychological batteryHIVNeurodegeneration pathwaysDysfunctionTherapy